Covaxin

Monthly production capacity of Covishield is projected to be increased to more than 120 million doses and of Covaxin to around 58 million doses by December, the government told Rajya Sabha today, citing information from the COVID-19 vaccine makers.

The supply of Bharat Biotech's Covaxin has been slowed down because the first few batches at the company's newest facility in Bengaluru were not of the right quality, a top government adviser has said.

Covaxin demonstrated 77.8 per cent effectiveness against symptomatic COVID-19 and 65.2 per cent protection against the B.1.617.2 Delta variant.

After suspending the proposed clinical trials of Bharat Biotech's COVID-19 vaccine Covaxin and a request for Emergency Use Authorisation, Brazil now has suspended its decision to import four million doses of the jab into that country.

After suspending the proposed clinical trials of Bharat Bioetch's Covaxin, Brazil has now scrapped the Emergency Use Authorisation request made by the Indian firm for the vaccine.

The Centre is purchasing Covishield and Covaxin doses at the rate of Rs 205 and Rs 215 per dose, respectively, and there is only a marginal difference in the purchase price of the two vaccines for the government, the Lok Sabha was informed on Friday.

Drugmaker Bharat Biotech on Friday said it has scrapped agreements with two Brazilian companies amid controversy over a $324 million deal between the South American country and Bharat Biotech for the import of 20 million doses of Covaxin.

Bharat Biotech today said it has committed to supply over 500 million doses of its COVID-19 vaccine Covaxin to the Centre under the countrywide immunisation programme.

Of the two vaccines presently being procured for the ongoing COVID-19 vaccination, Covishield has received the WHO pre-qualification, while the process of pre-qualification for Bharat Biotech's Covaxin is going on, the government informed Parliament.

With 2,77,870 doses left in Delhi's Covid vaccine bank on Monday morning, the vaccine stock will last for less than a day, according to a bulletin issued by the city government.

Officials of the World Health Organisation (WHO) had a meeting with the Bharat Biotech and its dossier for Emergency Use Listing of Covaxin is under review by technical experts, Dr Poonam Khetrapal Singh, Regional Director, WHO South-East Asia said.

The Centre has placed an order to procure 66 crore more doses of Covishield and Covaxin to be supplied between August and December this year, at a revised price of Rs 205 and Rs 215 per dose, respectively, excluding taxes, official sources said.

With a review process of Covaxin, the indigenous vaccine against COVID-19, commencing at the World Health Organisation, the Hyderabad-based Bharat Biotech on Monday said it expects to receive emergency use listing from the global body at the earliest

The World Health Organization (WHO) is likely to take a decision on including Bharat Biotech's COVID-19 vaccine Covaxin in the emergency use list (EUL) within four to six weeks, Soumya Swaminathan, the global health body's chief scientist has said.

With Punjab running out of coronavirus vaccine Covishield and left with only one day's stock of Covaxin, Chief Minister Amarinder Singh today reiterated the need for enhanced supplies from the Centre, his office said.

Monthly production capacity of Covishield is projected to be increased to more than 120 million doses and of Covaxin to around 58 million doses by December, the government told Rajya Sabha today, citing information from the COVID-19 vaccine makers.

The supply of Bharat Biotech's Covaxin has been slowed down because the first few batches at the company's newest facility in Bengaluru were not of the right quality, a top government adviser has said.

Covaxin demonstrated 77.8 per cent effectiveness against symptomatic COVID-19 and 65.2 per cent protection against the B.1.617.2 Delta variant.

After suspending the proposed clinical trials of Bharat Biotech's COVID-19 vaccine Covaxin and a request for Emergency Use Authorisation, Brazil now has suspended its decision to import four million doses of the jab into that country.

After suspending the proposed clinical trials of Bharat Bioetch's Covaxin, Brazil has now scrapped the Emergency Use Authorisation request made by the Indian firm for the vaccine.

The Centre is purchasing Covishield and Covaxin doses at the rate of Rs 205 and Rs 215 per dose, respectively, and there is only a marginal difference in the purchase price of the two vaccines for the government, the Lok Sabha was informed on Friday.

Drugmaker Bharat Biotech on Friday said it has scrapped agreements with two Brazilian companies amid controversy over a $324 million deal between the South American country and Bharat Biotech for the import of 20 million doses of Covaxin.

Bharat Biotech today said it has committed to supply over 500 million doses of its COVID-19 vaccine Covaxin to the Centre under the countrywide immunisation programme.

Of the two vaccines presently being procured for the ongoing COVID-19 vaccination, Covishield has received the WHO pre-qualification, while the process of pre-qualification for Bharat Biotech's Covaxin is going on, the government informed Parliament.

With 2,77,870 doses left in Delhi's Covid vaccine bank on Monday morning, the vaccine stock will last for less than a day, according to a bulletin issued by the city government.

Officials of the World Health Organisation (WHO) had a meeting with the Bharat Biotech and its dossier for Emergency Use Listing of Covaxin is under review by technical experts, Dr Poonam Khetrapal Singh, Regional Director, WHO South-East Asia said.

The Centre has placed an order to procure 66 crore more doses of Covishield and Covaxin to be supplied between August and December this year, at a revised price of Rs 205 and Rs 215 per dose, respectively, excluding taxes, official sources said.

With a review process of Covaxin, the indigenous vaccine against COVID-19, commencing at the World Health Organisation, the Hyderabad-based Bharat Biotech on Monday said it expects to receive emergency use listing from the global body at the earliest

The World Health Organization (WHO) is likely to take a decision on including Bharat Biotech's COVID-19 vaccine Covaxin in the emergency use list (EUL) within four to six weeks, Soumya Swaminathan, the global health body's chief scientist has said.

With Punjab running out of coronavirus vaccine Covishield and left with only one day's stock of Covaxin, Chief Minister Amarinder Singh today reiterated the need for enhanced supplies from the Centre, his office said.